Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis

for PsO. Ixekizumab is a humanized immunoglobulin G4 (IgG4 kappa) monoclonal antibody targeting interleukin (IL)-17A. It is highly efficacious in the treatment of plague PsO with and favorable

  • 0 views
  • 09 Jul, 2021
  • 1 location
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA

arthritis
  • 2 views
  • 11 Jul, 2022
  • 47 locations
Ixekizumab in Adult Patients With Lichen Planus and Lichen Planopilaris

To evaluate the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment (IGA) Score

  • 10 views
  • 05 Jun, 2022
  • 1 location
Targeting IL-17A for Treatment-Resistant Depression

The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).

  • 0 views
  • 27 Nov, 2021
  • 1 location
Assessing Patient Confidence in Biologic Medications

), interleukin 12/23 blockers (ustekinumab) and interleukin 17A blockers (secukinumab, ixekizumab). Due to biologic medication's efficacy and safety profiles, they have revolutionized dermatology and the

ixekizumab
ustekinumab
infliximab
certolizumab pegol
tumor necrosis factor alpha
  • 67 views
  • 04 Oct, 2022
  • 1 location